Effect of novel oral anticoagulants on Hospital Anxiety and Depression Scale scores Auswirkungen neuer oraler Antikoagulanzien auf den Punktwert in der Hospital Anxiety and Depression Scale
Herz, cilt.44, sa.8, ss.743-749, 2019 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 44 Sayı: 8
- Basım Tarihi: 2019
- Doi Numarası: 10.1007/s00059-019-4828-1
- Dergi Adı: Herz
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.743-749
- Anahtar Kelimeler: Atrial fibrillation, Quality of life, Hemorrhage, Warfarin, Non-vitamin K novel oral anticoagulant
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Background: The negative impact of atrial fibrillation (AF) on health-related quality of life has been extensively documented. The aim of this study was to compare the Hospital Anxiety and Depression Scale (HADS) scores of patients with non-valvular AF during warfarin administration and after switching to novel oral anticoagulants (NOACs). Methods: The study comprised 100 consecutive patients on warfarin treatment between July 2018 and January 2019 for whom a transition to NOACs was planned. All patients completed the HADS at the start of the study and at least 3 months after that date. Results: The mean value of HADS-A (5.9 ± 2.1 vs. 4.4 ± 1.6, p < 0.001) and HADS-D (4.4 ± 1.7 vs. 3.7 ± 1.4, p < 0.001) scores was significantly higher in patients when they used warfarin than when they switched to NOACs. Analysis revealed that there was a significant correlation between HADS-A and HADS-D scores with age and history of bleeding (p < 0.001). The highest scores were found for patients with a history of bleeding and age ≥75 years (p < 0.001). Conclusion: Our study demonstrates that patients with nonvalvular AF under treatment with NOACs had lower HADS-A and HADS-D scores compared with patients on warfarin treatment. These findings suggest that NOACs may increase the quality of life and decrease morbidity and mortality by reducing anxiety and depression.